MedTrace Logo

Adjuvant Radiotherapy for pT1b Esophageal Cancer After Submucosal Endoscopic Resection

NCT05499195 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 159

Last updated 2022-08-12

No results posted yet for this study

Summary

Endoscopic Resection (ER) is a crucial therapeutic and diagnostic method for superficial esophageal cancer. However, lymph node metastasis rate in pT1b patients is relatively high. Although, adjuavnt chemoradiotherapy is recommended, limied studies prove the superiority of additional adjuvant radiotherapy over ESD alone. This study aimed to further verify the efficacy of adjuvant radiotherapy in early-stage esophageal cancer after ESD.

Conditions

  • Esophageal Cancer

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2022-05-15
Completion
2022-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05499195 on ClinicalTrials.gov